1Department of Imaging Research, Barrow Neurological Institute, Phoenix, AZ, United States, 2National Comprehensive Cancer Network, Philadelphia, PA, United States
Dynamic susceptibility
contrast (DSC-MRI) MRI is routinely used for brain tumor imaging and has shown
promise as an early biomarker for treatment response. Conventional DSC-MRI is susceptible
to contrast agent leakage effects, reducing the reliability of the
resulting blood volume maps. The use of a simplified spin and gradient echo (SAGE) sequence,
combined with robust processing strategies for correction of leakage effects, could
facilitate more rapid clinical translation and adoption of DSC-MRI for brain
tumor imaging. Taken together, the simplified SAGE approach and subsequence leakage correction provides a clinically feasible strategy for the simultaneous assessment tumor
perfusion, permeability and cellularity.
